With 20.47 million shares changed hands, the volume of the stock remained lighter than its average volume of 22.61 million shares. During the session, the Drug Manufacturers – Specialty & Generic company that operates in wider Healthcare sector, reached to the highest price of $1.6900 whereas the lowest price it dropped to was $1.6300. The 52-week range on TLRY shows that it touched its highest point at $3.40 and its lowest point at $1.50 during that stretch. It currently has a 1-year price target of $2.54. Beta for the stock currently stands at 2.32.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of TLRY was down-trending over the past week, with a drop of -8.84%, but this was down by -12.23% over a month. Three-month performance dropped to -13.16% while six-month performance fell -44.82%. The stock lost -40.43% in the past year, while it has lost -28.26% so far this year. A look at the trailing 12-month EPS for TLRY yields -2.28 with Next year EPS estimates of -0.09. For the next quarter, that number is -0.05. This implies an EPS growth rate of 90.61% for this year and 60.87% for next year. EPS is expected to grow by 37.00% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -23.57%.
Float and Shares Shorts:
At present, 742.73 million TLRY shares are outstanding with a float of 732.79 million shares on hand for trading. On Feb 15, 2024, short shares totaled 120.35 million, which was 15.94% higher than short shares on Jan 12, 2024. In addition to Mr. Irwin David Simon as the firm’s President, CEO & Chairman, Mr. Carl A. Merton CA, CBV, CPA serves as its CFO & Principal Accounting Officer.
Institutional Ownership:
Through their ownership of 11.14% of TLRY’s outstanding shares, institutional investors have minority control over the company.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for TLRY since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.
Dividends & Yield:
In terms of dividends, TLRY has a current ratio of $––, which is $–– over the trailing 12-months, while a dividend of $–– is likely to be paid on average over the next five years. Dividend yield is another indicator that appeals to many investors, and TLRY currently yields $0.00. In the past year, TLRY’s dividend yield has been $0.00, but when looking at the stock over the past five years, its yield has been $–. Accordingly, TLRY has a current buyback yield of $0.00. This was $0.00 for the TTM, and it was $– for the past five years.
Summary of Insider Activity:
Insiders traded TLRY stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 27 while that of sell transactions has risen to 23 over the past year. The total number of shares bought during that period was 3,783,368 while 1,928,333 shares were sold.
